GlassScriptPhysician profile
Celeste B Beaudoin
NPI 1639481690
$1,679.14
in general payments reported to CMS, 2019-2025
30 companies · $24.27 in 2025
The $24.27 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $124 · 2021: $426 · 2022: $409 · 2023: $228 · 2024: $126 · 2025: $24.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $317.41 | 2019-2023 | Liletta, Orilissa, Lo Loestrin Fe |
| Medtronic, INC. | $242.01 | 2021-2022 | |
| Pfizer INC. | $146.36 | 2019-2023 | |
| Organon LLC | $125.97 | 2024 | |
| Daiichi Sankyo INC. | $114.60 | 2019-2022 | |
| Therapeuticsmd, INC. | $88.47 | 2019-2022 | |
| Aspira Women'S Health INC | $60.14 | 2021-2023 | Ova1 |
| Roche Diagnostics Corporation | $53.95 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $45.87 | 2023 | |
| Vertical Pharmaceuticals, LLC | $45.74 | 2019 | |
| Lupin INC. | $39.51 | 2019 | |
| Evofem Biosciences, INC. | $36.68 | 2021-2022 | |
| Avanos Medical | $30.63 | 2021-2022 | |
| Millicent US INC | $29.74 | 2020 | |
| Baxter Healthcare | $27.54 | 2023 | Seprafilm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $26.89 | 2019-2023 | Veozah |
| Amgen INC. | $26.87 | 2021 | |
| Optumhealth Care Solutions, LLC | $24.27 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Amag Pharmaceuticals, INC. | $22.57 | 2019 | |
| Exeltis, USA INC. | $20.40 | 2023 | Slynd |
| Novo Nordisk INC | $17.71 | 2021 | |
| Agile Therapeutics, INC. | $17.48 | 2023 | Twirla |
| Acessa Health INC. | $16.96 | 2020 | |
| Myovant Sciences INC. | $15.86 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.45 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.32 | 2021 | |
| Abbott Laboratories | $14.51 | 2022 | |
| Coopersurgical, INC. | $14.45 | 2019 | |
| Sumitomo Pharma America, INC. | $12.92 | 2023 | Myfembree |
| Hologic Sales and Service, LLC | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Beaudoin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.